TL1A Expression in Psoriatic Skin

NCT01744327 | Unknown

• 1 other identifier: 331536
• Study Type: observational
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

TL1A is a newly discovered signal molecule that may be crucially involved in the maintenance of chronic inflammatory disorders. TL1A has also been demonstrated in psoriatic skin but the importance of TL1A in psoriasis is still unknown. Understanding inflammatory signal molecules in psoriasis is important because the development of new drugs directed against relevant signal molecules (e.g. TNF-α and IL12/23) has proved to be a very efficacious treatment principle. However, despite the dramatic progress in therapeutic options during the last decade, there is still a fraction of patients that are insufficiently treated with the currently available therapies. TL1A has been claimed to be the next important target for development of biologics in the field of chronic inflammation.

Conditions

Psoriasis

Outcome Measures

Primary Outcomes (1)

• Expression of TL1A in psoriatic skin

  Staining intensity of TL1A by IHC in involved psoriatic skin compared to uninvolved and skin from normal controls

  3 months

Study Arms (1)

Chronic Plaque type psoriasis

Patients with plaque type psoriasis

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Plaque type psoriasis

You may qualify if:

• Plaque type psoriasis
• at least 6 month history of psoriasis

You may not qualify if:

• systemic anti-psoriatic medication
• topical anti-psoriatic medication (wash-out period 2 weeks)

Sponsors & Collaborators

• Bispebjerg Hospital: lead
• AbbVie: collaborator
• University of Copenhagen: collaborator

Study Sites (1)

Department of dermatology D40 , Bispebjerg Hospital

Copenhagen, 2400 NV, Denmark

Location

MeSH Terms

Conditions

Psoriasis

Condition Hierarchy (Ancestors)

Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief Physician, Associate Professor

Study Record Dates

• First Submitted: December 5, 2012
• First Posted: December 6, 2012
• Study Start: December 1, 2012
• Primary Completion: December 1, 2013
• Last Updated: May 29, 2013

Record last verified: 2013-05

Locations

DK (1)